Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors - Lemieux, C; Gelinas, Y; Lalonde, J; Labrie, F; Cianflone, K; Deshaies, Y (J Lipid Res, 2005)